The impact of losartan on the lifetime incidence of ESRD and costs in Mexico

Revista de Investigacion Clinica

Volumn 57, Issue 3, 2005, Pages 399-405

  Arredondo, Armando ^a   Burke, Thomas A ^b   Carides, George W ^b   Lemus, Edith ^c   Querol, Julio ^c  

^a INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Outcomes Research   (Mexico)

Author keywords

Angiotensin II receptor antagonist; Cost; Cost effectiveness; Economics; End stage renal disease; Losartan; Type 2 diabetes mellitus

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIURETIC AGENT; LOSARTAN; PLACEBO;

ACCOUNTING; ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DOUBLE BLIND PROCEDURE; ECONOMIC EVALUATION; HEALTH CARE COST; HEMODIALYSIS; HUMAN; INCIDENCE; KIDNEY FAILURE; LIFE EXPECTANCY; LIFESPAN; MAJOR CLINICAL STUDY; MEXICO; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE PAYMENT; PUBLIC HOSPITAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, PUBLIC; HUMANS; HYPERTENSION; INCIDENCE; INSURANCE, HEALTH, REIMBURSEMENT; KIDNEY FAILURE, CHRONIC; LIFE EXPECTANCY; LOSARTAN; MALE; MEXICO; MIDDLE AGED; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RENAL REPLACEMENT THERAPY; RISK; SURVIVAL ANALYSIS;

EID: 24044523822     PISSN: 00348376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. García PM, et al. Las múltiples facetas de la investigación en Salud. México, DF. IMSS; 2001, pp. 153-70.
2. Keane H. Advances in slowing the progress of diabetic nephropathy. Patient Care 2001; 30: 28-41.
3. Rodríguez Moctezuma. Características epidemiológicas de pacientes con diabetes-IRC en el Estado de México. Rev Med IMSS 2003; 41(5): 383-59.
4. Brien H, Garcia H, Garcia G, et al. Epidemiología de la insuficiencia renal crónica en Jalisco. Boletín Colegio Jalisciense Nefrología 2001; 5: 6-8.
5. Cueto-Manzano AM. Peritoneal dialysis in Mexico. Kidney International 2003; 63(Supl. 83): S90-S92.
6. Brenner BM, Cooper ME, De Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
7. Herman WH, Shahinfar S, Carides GW, et al. Losartan reduces the costs associated with diabetic end-stage renal disease. Diabetes Care 2003; 26(3): 683-7.
8. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York: Wiley, 1980.
9. Lawless JF. Statistical Models and Methods for Lifetime Data. New York: Wiley, 1982.
10. Akaike H. Information Theory and an extension of the maximum likelihood principle. In: 2nd International Symposium of Information Theory and Control. EBN Petrov and F Csaki (Eds.). Budapest: Akademia Kiado; 1973, pp. 267-81.
11. Arredondo A. Costs for health care interventions in Mexican Health System. Mexico: National Institute of Public Health; 2004.
12. Arredondo A. Financial requirements for health services demands for diabetes and hypertension in Mexico: 2001-2003. Rev Invest Clin 2001; 53(5): 422-9.
13. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman and Hall; 1993.
14. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: Public health implications from the RENAAL study for the European Union. Kidney International 2002; 62(Suppl. 82): S68-S72.
15. Gerth WC, Ribeiro AB, Ferder LF, et al. Losartan reduces the burden of end-stage renal disease: Public Health Implications from the RENAAL Study for Latin America. Sociedad Iberoamericana de Información Científica (SIIC). In Press.
16. UK National Institute for Clinical Excellence. Guide to the methods of technology appraisal. UK National Health Service; 2004.